Inhibitor Therapeutics (OTCMKTS:INTI) Releases Earnings Results

Inhibitor Therapeutics (OTCMKTS:INTI) posted its earnings results on Friday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.

Inhibitor Therapeutics Stock Down 3.3 %

Shares of Inhibitor Therapeutics stock opened at $0.06 on Friday. The firm has a market cap of $9.99 million, a price-to-earnings ratio of -5.80 and a beta of -0.55. Inhibitor Therapeutics has a twelve month low of $0.04 and a twelve month high of $0.14. The business has a 50-day moving average price of $0.06 and a 200-day moving average price of $0.07.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.